Brand Name

Tygacil

Generic Name
Tigecycline
View Brand Information
FDA approval date: June 15, 2008
Classification: Tetracycline-class Antibacterial
Form: Injection

What is Tygacil (Tigecycline)?

TYGACIL is a tetracycline class antibacterial indicated in patients 18 years of age and older for: Complicated skin and skin structure infections.

Approved To Treat

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Therapeutic Strategies for Carbapenem-Resistant Acinetobacter Baumannii Infections: Study Protocol

Summary: CRAB infections in ICUs are on the rise, leading to higher morbidity, mortality, and healthcare costs due to resistance to most antibiotics, including carbapenems. The main resistance mechanisms include carbapenemases, efflux pumps, and changes in the bacterial cell wall. Current treatments include polymyxins (Colistin, Polymyxin B), which are effective but can lead to resistance, aminoglycosides ...

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT)

Summary: Mycobacterium abscessus (MABS) is a group of rapid-growing, multi-drug resistant non-tuberculous mycobacteria (NTM) causing infections in humans. MABS pulmonary disease (MABS-PD) can result in significant morbidity, increased healthcare utilisation, accelerated lung function decline, impaired quality of life, more challenging lung transplantation, and increased mortality. While the overall numbers...

Randomized Trial to Study the Effect of Rifaximin on Gut Microbiome Diversity Post Allogeneic Stem Cell Transplant in Acute Leukemia.

Objective: To determine the impact of rifaximin on gut microbial diversity and compare it with controls. * Secondary